DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Overview | Financials
Company Name DiaMedica Therapeutics Inc.
Symbol DMAC
Currency USD
Price 4.03
Market Cap 172,273,634
Dividend Yield 0%
52-week-range 1.938 - 4.07
Industry Biotechnology
Sector Healthcare
CEO Mr. Dietrich John Pauls MBA
Website https://www.diamedica.com

An error occurred while fetching data.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type

Related Stocks

InflaRx N.V. logo

InflaRx N.V.

IFRX

1.52 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.285 USD

Orgenesis Inc. logo

Orgenesis Inc.

ORGS

0.59 USD

Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

AKBA

1.35 USD

Streamline Health Solutions, Inc. logo

Streamline Health Solutions, Inc.

STRM

0.526 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

MediWound Ltd. logo

MediWound Ltd.

MDWD

16.6 USD

Financials

Numbers are in millions USD

Numbers are in millions USD